FDC Limited has received formal approval from the United States Food and Drug Administration (U.S. FDA) for its Cefixime for Oral Suspension USP. This approval covers two strengths: 100 mg/5 mL and 200 mg/5 mL. This milestone marks a significant step in the company’s efforts to expand its pharmaceutical product portfolio in the international market, specifically within the United States.
Expanding US Market Presence
On May 18, 2026, FDC Limited announced that it has successfully secured regulatory clearance from the U.S. FDA for its Cefixime oral suspension. The authorization includes the 100 mg/5 mL and 200 mg/5 mL dosages, which are critical additions to the company’s offerings. This development underlines the company’s commitment to delivering quality healthcare solutions to global markets.
Strategic Significance
Cefixime is a widely utilized antibiotic, and obtaining this approval allows FDC Limited to tap into the U.S. market, which represents a key growth region for the firm’s export segment. By receiving this authorization, the company is well-positioned to commence the commercialization and distribution of these specific suspension formulations to pharmacy networks and healthcare providers throughout the United States.
Source: BSE
